28.78
+0.29(+1.02%)
Currency In USD
| Previous Close | 28.49 |
| Open | 28.59 |
| Day High | 29.13 |
| Day Low | 28.23 |
| 52-Week High | 71.9 |
| 52-Week Low | 24.34 |
| Volume | 1.01M |
| Average Volume | 2.9M |
| Market Cap | 3.58B |
| PE | -14.46 |
| EPS | -1.99 |
| Moving Average 50 Days | 31.83 |
| Moving Average 200 Days | 35.63 |
| Change | 0.29 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $2,051.32 as of February 05, 2025 at a share price of $28.78. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $664.2 as of February 05, 2025 at a share price of $28.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
GlobeNewswire Inc.
Jan 27, 2025 9:00 PM GMT
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month treatment of adult patien
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 13, 2025 2:00 PM GMT
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 E
Apellis Announces Keli Walbert to Join the Board of Directors
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmac